Incidence and prognostic value of recurrent chromosomal abnormalities in elderly patients with multiple myeloma
Abstract
Evaluation of: Avet-Loiseau H, Hulin C, Campion L et al. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome experience. J. Clin. Oncol. 31(22), 2806–2809 (2013). Chromosomal abnormalities are well-established biomarkers used in the subclassification and risk stratification of multiple myeloma patients. Patients with t(4;14)(p16;q32) and deletion 17p13 are considered to have a poor prognosis, and do not respond to any of the available therapies. However, most studies of chromosomal abnormalities incidence and risk stratification have been performed in patients younger than 66 years of age; therefore we have very limited data on the elderly population. This study was designed to uncover the incidence and clinical significance of 17p13 and 13q14 deletions and t(4;14) in a large cohort of clinically annotated multiple myeloma patients older than 66 years of age. Interestingly, the incidence of deletion of 13q14 and t(4;14) decreased with age, being significantly lower in patients >75 years old than in patients <75 years old. Conversely, the incidence of deletion 17p13 was not different between groups. Importantly, this study confirmed that t(4;14) and deletion 17p13 maintain a poor prognosis value in the elderly (66–75 years old) and the very elderly population (>75 years old), regardless of the treatment received.
References
- 1 Rajkumar SV, Jacobus S, Callander NS et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol.11(1),29–37 (2010).
- 2 Richardson PG, Mitsiades C, Schlossman R et al. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev. Anticancer Ther.8(7),1053–1072 (2008).
- 3 San Miguel JF, Schlag R, Khuageva NK et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med.359(9),906–917 (2008).
- 4 Fonseca R, Barlogie B, Bataille R et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res.64(4),1546–1558 (2004).
- 5 Fonseca R, Bergsagel PL, Drach J et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia23(12),2210–2221 (2009).
- 6 Avet-Loiseau H, Attal M, Moreau P et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood109(8),3489–3495 (2007).
- 7 Fonseca R, Blood E, Rue M et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood101(11),4569–4575 (2003).
- 8 Avet-Loiseau H, Soulier J, Fermand JP et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia24(3),623–628 (2010).
- 9 Reece D, Song KW, Fu T et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood114(3),522–525 (2009).
- 10 Kapoor P, Kumar S, Fonseca R et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood114(3),518–521 (2009).
- 11 Kapoor P, Fonseca R, Rajkumar SV et al. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin. Proc.85(6),532–537 (2010).
- 12 Mateos MV, Gutierrez NC, Martin-Ramos ML et al. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. Blood118(17),4547–4553 (2011).
- 13 Avet-Loiseau H, Hulin C, Campion L et al. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myelome experience. J. Clin. Oncol.31(22),2806–2809 (2013).
- 14 Annunziata CM, Davis RE, Demchenko Y et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell12(2),115–130 (2007).
- 15 Chapman MA, Lawrence MS, Keats JJ et al. Initial genome sequencing and analysis of multiple myeloma. Nature471(7339),467–472 (2011).
- 16 Keats JJ, Fonseca R, Chesi M et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell12(2),131–144 (2007).
- 17 Chng WJ, Braggio E, Mulligan G et al. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood111(3),1603–1609 (2008).
- 18 Shaughnessy JD Jr., Zhan F, Burington BE et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood109(6),2276–2284 (2007).
- 19 Decaux O, Lode L, Magrangeas F et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J. Clin. Oncol.26(29),4798–4805 (2008).
- 20 Kuiper R, Broyl A, de Knegt Y et al. A gene expression signature for high-risk multiple myeloma. Leukemia26(11),2406–2413 (2012).
